The REPRESSIT consortium is arranging a symposium at Karolinska Institute in Stockholm on the 16th of June 2026 with the title: REPRESSIT or NOT:What is the future of immune checkpoint inhibitors? This symposium has the purpose of bringing together scientists with unique expertise, including immunology, protein design and therapeutic development to share their knowledge and…
REPRESSIT Consortium meets in Oxford – 2025
As we near the completion of the second year of REPRESSIT, all members of the consortium gathered in Oxford on 10th-11th February 2025. The meeting was hosted by the Fernandes Lab at the University of Oxford. Participants from all five project partners -Oxford, AMOLF, UKB, UMCU and KI- discussed the progress made so far, ongoing…
First year of REPRESSIT
In the complex world of cancer, immune cells called T cells are a critical part of our bodies’ arsenal to combat tumor cells. They play a crucial role in “finishing the job” when patients are treated for cancer with chemotherapy or radiation. Unfortunately, in some patients, these cells are often ‘shut down’ by inhibitory immune…